Neoadjuvant and Adjuvant Pembrolizumab in Resectable Locally Advanced, Human Papillomavirus-Unrelated Head and Neck Cancer: A Multicenter, Phase 2 Trial is a research paper published in medRxiv (2020). On theSindex it has a DataRank of 0.396. It has been cited 4 times, with 3 citing works in its 1-hop citation network.
Scored on demand from live citation data
Linked data & code
DataRank reads this dataset's downstream impact straight off the citation graph — no black box, no proprietary weighting. How is this computed?
FAIR checklist signals are shown for context only and do not affect DataRank scoring.
We only score data papers we can read in full — never from an abstract alone.
Base Score Contribution
0.241
From this paper's citation signal
Citation Network Contribution
0.155
From 3 citing papers with measurable signal
Ranked by each citer's contribution to N(p) — log1p(Cq) divided by its reference count — out of 3 citers.
National Institutes of Health
Grant: 5P30CA091842-05
Core--Pharmacology Facility
National Institutes of Health
Grant: 4R00HG007940-03
Integrated Analysis & Interpretation of Whole Genome Exome & Transcriptome Sequen
National Institutes of Health
Grant: 5U01CA209936-03
DEVELOPMENT OF INFORMATICS RESOURCES FOR INTERPRETATION OF CLINICALLY ACTIONABLE VARIANTS IN CANCER
National Institutes of Health
Grant: 5R01DE024403-03
GENOMIC INSIGHTS AND THERAPEUTIC TARGETING OF ORAL CANCER TUMOR INITIATING CELLS
National Institutes of Health
Grant: 5R01DE027736-04
Immunotherapeutic responses to neoantigens in head and neck cancer
National Institutes of Health
Grant: 1K22CA188163-01
DEFINING THE REGULATORY, NON-CODING, MUTATIONAL LANDSCAPE OF BREAST CANCER
National Institutes of Health
Grant: 1U24CA237719-01
Standardized and Genome-Wide Clinical Interpretation of Complex Genotypes for Cancer Precision Medicine
Fields of Study
Keywords
Sustainable Development Goals